• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy.

作者信息

VanderWeele David J, Antonarakis Emmanuel S, Carducci Michael A, Dreicer Robert, Fizazi Karim, Gillessen Silke, Higano Celeste S, Morgans Alicia K, Petrylak Daniel P, Sweeney Christopher J, Hussain Maha

机构信息

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

出版信息

J Clin Oncol. 2019 Nov 10;37(32):2961-2967. doi: 10.1200/JCO.19.01595. Epub 2019 Sep 10.

DOI:10.1200/JCO.19.01595
PMID:31498754
Abstract
摘要

相似文献

1
Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy.转移性激素敏感性前列腺癌：在迅速发展的延长生命治疗格局中的临床决策制定
J Clin Oncol. 2019 Nov 10;37(32):2961-2967. doi: 10.1200/JCO.19.01595. Epub 2019 Sep 10.
2
[French CCAFU guidelines on prostate cancer: hormono-naive metastatic prostate cancer - update 2017].[法国泌尿生殖系统癌症联合会（CCAFU）前列腺癌指南：激素初治转移性前列腺癌——2017年更新]
Prog Urol. 2018 May;28(6):303-306. doi: 10.1016/j.purol.2018.03.006. Epub 2018 Apr 19.
3
A Framework for Treatment Decision Making at Prostate Cancer Recurrence.前列腺癌复发治疗决策框架。
Med Decis Making. 2017 Nov;37(8):905-913. doi: 10.1177/0272989X17711913. Epub 2017 May 31.
4
The Conundrum of Treating de novo metastatic Hormone-Sensitive Prostate Cancer.治疗初发性转移性激素敏感性前列腺癌的难题
Sci Rep. 2025 Apr 11;15(1):12500. doi: 10.1038/s41598-025-96065-9.
5
Influence of an International Consensus Conference on Practice Patterns in Advanced Prostate Cancer.一场国际共识会议对晚期前列腺癌治疗模式的影响
Eur Urol. 2018 Aug;74(2):239-240. doi: 10.1016/j.eururo.2018.04.024. Epub 2018 May 3.
6
[The difficult choice: when not to treat. Hormone-refractory metastatic prostate cancer].艰难的抉择：何时不进行治疗。激素难治性转移性前列腺癌
Suppl Tumori. 2004 Jul-Aug;3(4):S93.
7
Introduction by the Guest Editor: The Rapidly Evolving Treatment Landscape of Prostate Cancer-The Convergence of Treatment Paradigms of Localized and Metastatic Diseases.客座编辑引言：前列腺癌快速演变的治疗格局——局限性疾病与转移性疾病治疗模式的融合
Cancer J. 2020 Jan/Feb;26(1):1. doi: 10.1097/PPO.0000000000000431.
8
Prostate Cancer Screening-A New Recommendation for Meaningful Physician-Patient Conversations.前列腺癌筛查——关于开展有意义的医患对话的新建议。
JAMA Oncol. 2018 Aug 1;4(8):1049-1050. doi: 10.1001/jamaoncol.2018.1492.
9
Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?新成像技术快速发展时代新诊断的高危前列腺癌：我们如何治疗？
J Clin Oncol. 2021 Jan 1;39(1):13-16. doi: 10.1200/JCO.20.02268. Epub 2020 Oct 13.
10
Treatment: When less is more.治疗：少即是多。
Nature. 2015 Dec 17;528(7582):S126-7. doi: 10.1038/528S126a.

引用本文的文献

1
Prevalence and Spectrum of Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer.转移性去势抵抗性前列腺癌患者在不同疾病状态下循环肿瘤 DNA 中检测到的配体结合域突变的流行率和谱。
JCO Precis Oncol. 2024 May;8:e2300330. doi: 10.1200/PO.23.00330.
2
Looking for a Simplified Diagnostic Model to Identify Potentially Lethal Cases of Prostate Cancer at Initial Diagnosis: An ImGO Pilot Study.寻找一种简化诊断模型以在前列腺癌初诊时识别潜在致命病例：一项ImGO初步研究
Cancers (Basel). 2022 Mar 17;14(6):1542. doi: 10.3390/cancers14061542.
3

本文引用的文献

1
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.阿比特龙在“高-”和“低-”风险转移性激素敏感前列腺癌中的应用。
Eur Urol. 2019 Dec;76(6):719-728. doi: 10.1016/j.eururo.2019.08.006. Epub 2019 Aug 23.
2
Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.肺转移前列腺癌的基因组和临床特征：一种独特的分子亚型。
Prostate. 2019 Sep;79(13):1572-1579. doi: 10.1002/pros.23881. Epub 2019 Aug 7.
3
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?
在转移性去势敏感性前列腺癌（MCSPC）中，哪些患者从多西他赛联合雄激素剥夺治疗（ADT）中获益最大？
Acta Clin Croat. 2019 Nov;58(Suppl 2):73-75. doi: 10.20471/acc.2019.58.s2.12.
4
Epigenetics in prostate cancer: clinical implications.前列腺癌中的表观遗传学：临床意义。
Transl Androl Urol. 2021 Jul;10(7):3104-3116. doi: 10.21037/tau-20-1339.
5
Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer.肿瘤抑制基因（TP53、PTEN、RB1）改变对转移性、激素敏感型前列腺癌的影响及治疗结局的差异。
Prostate Cancer Prostatic Dis. 2022 Sep;25(3):479-483. doi: 10.1038/s41391-021-00430-4. Epub 2021 Jul 22.
6
Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer.接受多西他赛治疗转移性激素敏感前列腺癌的老年男性的结局。
Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1181-1188. doi: 10.1038/s41391-021-00389-2. Epub 2021 May 18.
7
Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From "All-Comers" to "Personalized" Approach.转移性去势敏感性前列腺癌的治疗策略：从“所有患者”到“个性化”方法。
Onco Targets Ther. 2021 May 5;14:2967-2974. doi: 10.2147/OTT.S306345. eCollection 2021.
8
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.转移性去势敏感型前列腺癌中的致癌基因组改变、临床表型和结果
Clin Cancer Res. 2020 Jul 1;26(13):3230-3238. doi: 10.1158/1078-0432.CCR-20-0168. Epub 2020 Mar 27.
ARCHES：雄激素剥夺治疗联合恩扎卢胺或安慰剂治疗转移性去势敏感性前列腺癌的随机 III 期研究。
J Clin Oncol. 2019 Nov 10;37(32):2974-2986. doi: 10.1200/JCO.19.00799. Epub 2019 Jul 22.
4
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.恩扎卢胺联合标准一线治疗转移性前列腺癌。
N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.
5
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.阿帕鲁胺治疗转移性去势敏感性前列腺癌。
N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31.
6
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.醋酸阿比特龙联合泼尼松治疗新诊断的高危转移性去势敏感性前列腺癌（LATITUDE）：一项随机、双盲、III 期临床试验的最终总生存分析。
Lancet Oncol. 2019 May;20(5):686-700. doi: 10.1016/S1470-2045(19)30082-8. Epub 2019 Apr 12.
7
Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.转移性去势敏感性前列腺癌的前列腺放射治疗：STOPCAP 系统评价和荟萃分析。
Eur Urol. 2019 Jul;76(1):115-124. doi: 10.1016/j.eururo.2019.02.003. Epub 2019 Feb 28.
8
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.局部和转移性前列腺癌中 TP53、PTEN 和 RB1 肿瘤抑制因子的复合基因组改变。
Eur Urol. 2019 Jul;76(1):89-97. doi: 10.1016/j.eururo.2018.11.045. Epub 2018 Dec 12.
9
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.新诊断转移性前列腺癌原发肿瘤放疗（STAMPEDE）：一项随机对照 3 期试验。
Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3. Epub 2018 Oct 21.
10
Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.在一项前瞻性随机临床试验中，比较单纯去势治疗与去势治疗联合前列腺同期放疗对原发性骨转移前列腺癌患者生存的影响：来自 HORRAD 试验的数据。
Eur Urol. 2019 Mar;75(3):410-418. doi: 10.1016/j.eururo.2018.09.008. Epub 2018 Sep 25.